Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. announced on June 1, 2025, the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2, global, multicenter study of zipalertinib in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations who have received prior therapy.
The full publication, titled "Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab," provides detailed findings. These results support zipalertinib as a potential targeted therapy option for patients living with previously treated recurrent or metastatic NSCLC harboring EGFR ex20ins mutations, where oral targeted therapies are currently lacking.
The publication of these pivotal data in a prestigious journal enhances the scientific validation of zipalertinib. Taiho Oncology is actively recruiting patients for the Phase 3 REZILIENT3 trial, which further underscores the commitment to advancing zipalertinib as a potential new standard of care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.